| __timestamp | MannKind Corporation | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 1213000 |
| Thursday, January 1, 2015 | 108402000 | 3425000 |
| Friday, January 1, 2016 | 46928000 | 6311000 |
| Sunday, January 1, 2017 | 74959000 | 9518000 |
| Monday, January 1, 2018 | 79716000 | 28080000 |
| Tuesday, January 1, 2019 | 74669000 | 36550000 |
| Wednesday, January 1, 2020 | 59040000 | 46125000 |
| Friday, January 1, 2021 | 77417000 | 68486000 |
| Saturday, January 1, 2022 | 91473000 | 92032000 |
| Sunday, January 1, 2023 | 94314000 | 117532000 |
Cracking the code
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, MannKind Corporation and Rhythm Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses. From 2014 to 2023, MannKind's expenses have fluctuated, peaking in 2015 and 2023, with a notable 15% increase in the latter year. Meanwhile, Rhythm Pharmaceuticals has experienced a dramatic rise, with expenses surging by over 9,600% from 2014 to 2023. This sharp increase reflects Rhythm's aggressive expansion and investment in its operations. As of 2023, Rhythm's SG&A expenses have surpassed MannKind's, indicating a shift in financial strategy. These trends highlight the dynamic nature of the biopharmaceutical industry, where strategic financial management can significantly impact a company's market position.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation